Hsiao, Chih-YangChih-YangHsiaoREY-HENG HUPO-CHIN LIANGCHIH-HORNG WU2025-08-282025-08-282025-07https://scholars.lib.ntu.edu.tw/handle/123456789/731665Background: Repeat hepatic resection (re-resection) and radiofrequency ablation (RFA) are both standard treatments for small recurrent hepatocellular carcinoma (HCC) after curative resection. This study compares long-term outcomes of these treatments. Methods: This retrospective study included patients with recurrent HCC smaller than 3 cm treated with re-resection or RFA from 2001 to 2019 in a tertiary center. Propensity score matching (PSM) minimized baseline differences. Primary outcomes were overall survival (OS) and disease-free survival (DFS). Subgroup analyses explored outcomes based on recurrence interval, hepatitis infection status, and RFA guidance method (ultrasound [US] versus computed tomography [CT]). Multivariate Cox regression identified predictors of survival and secondary recurrence. Results: After PSM, 106 patients in the re-resection group and 106 in the RFA group were compared. OS rates at 3, 5, and 8 years for re-resection were 97.9%, 85.4%, and 75.8%, compared to 87.8%, 77.9%, and 62.8% for RFA (p = 0.15). DFS rates were 53.3%, 41.8%, and 26.7% for re-resection versus 43.9%, 28.1%, and 24.0% for RFA (p = 0.15). Subgroup analysis indicated re-resection was superior in early recurrence (<24 months) and HBV-related HCC. US-guided and CT-guided RFA showed no significant differences in OS or DFS. HCV infection and multiple tumors were independent predictors of secondary recurrence. Conclusion: Repeat hepatic resection and RFA offer comparable survival for small recurrent HCC. Re-resection is preferred for early recurrence and HBV-related HCC. US- and CT-guided RFA are equally effective alternatives.enfalsejournal article10.2147/JHC.S4964702-s2.0-105011537596